Biomarkers of nivolumab benefit in resectable non-small cell lung cancer – Nature0

• SCIENCE, Science / Health, Science Mission Directorate, scientists, Space, Space Communications & Navigation Program, Space Launch System (SLS), Space Telescope, space-x-ipo, SpaceX
• August 13, 2026

Exploratory biomarker analyses were performed in 190 patients (nivolumab, 98 out of 229 (43%); placebo, 92 out of 232 (40%)) with evaluable paired tumour samples from screening and blood samples from ≥1 time point during the study for whole-exome sequencing (WES). These individuals constituted the biomarker-evaluable population. The most common reasons for exclusion were samples